Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
CNS Fungal Infections Neuropathology Conference Robyn Massa, MD and Clayton Wiley, MD, PhD January 26, 2015 Case Report: History • HPI: 64 yo M initially presenting to OSH on 6/24/13 and transferred to PUH on 6/26/13 with new onset daily 10/10 headaches for 2 months. Headaches are diffuse and feel like pressure. • Associated symptoms: lightheadedness, nausea, right ear pain, mild neck stiffness, “staggering” gait, 8lb wound loss in 2 weeks • Denies: photophobia, phonophobia, vision changes, fevers, night sweats, travel, sick contacts • Later revealed has had change in affect, cognitive slowing, and generalized weakness History continued • PMH: Nephrolithiasis, “spot on lungs” • SH: Denies tobacco/etoh/drugs. Lives with wife. Unemployed. • FH: Father had rectal cancer • Medications: none • Allergies: NKDA • ROS: As per HPI Physical Exam • • • • • VS: T 36.2, BP 155/70, HR 73, RR 14, Pulse ox 98% Gen: NAD. Sleepy but easily arousable. Cachectic appearing Neck: Moderately decreased ROM in the “yes-yes” motion Heent, Resp, CV, GI exams wnl Neuro: • MS: Alert and oriented to person, place, date. Sleepy but easily arousable to voice. Speech fluent and appropriate. Cognition and memory grossly intact • CN: Intact • Motor: Full and symmetric strength throughout • Sensory: Intact to vibration and temperature throughout • Reflexes: 2+ throughout. Flexor plantar responses. • Coordination: No dysmetria, normal RAMs • Gait: Patient reported severe lightheadedness on standing. Gait was somewhat unsteady and slowed but not ataxic OSH Data • CMP, CBC wnl • CSF: xanthrochromic • WBC 16 (neut 1, lymph 61), RBC 255 • Protein 254, Glucose 3 • Gram stain: no organisms, moderate WBCs • CSF culture: pending at time of transfer • Brain MRI w/wout contrast: “unremarkable” • CTA head and neck: “patent vessels” • Lumbar puncture #2 attempted at a different OSH but unsuccessful Differential Diagnosis • • • • • Bacterial meningitis Fungal meningitis Viral meningitis/encephalitis Leptomeniningeal metastasis Paraneoplastic syndrome Initial Labs • Serum labs notable for mild leukocytosis 12.5 • WNL: ESR, CRP, RPR • Lumbar puncture #2 • Opening pressure: “oscillated between 26 and 32cm H20,” clear fluid WBC Neut Lymph Mono RBC Glucose Protein Tube 3 206 10 50 27 333 <10 Tube 4 211 41 29 24 319 • Micro pending 280 What happened next • Empirically started Ampicillin, Ceftriaxone, Vancomycin, Acyclovir • Consulted Infectious Disease team • However later that afternoon… • CRYPTOCOCCAL ANTIGEN = POSITIVE with a titer of 1:2048 • Patient started on induction treatment x 4 weeks: • Liposomal amphotericin 250mg (4mg/kg) IV q24h • Flucytosine 1500mg (25mg/kg) PO q6h • Planned for consolidation treatment with Fluconazole Cryptococcal Meningitis (CM): Epidemiology • Encapsulated saprophytic yeast, transmitted by inhalation • Human pathogens • C. neoformans • C. neoformans var. grubii: most common, 82% of disease worldwide • C. neorformans var. neoformans • C. gattii: immunocompetent individuals in tropical and subtropical regions; sporadic cases in North America • Mostly affects those with impaired cell-mediated immunity • HIV: 95% in middle to low income countries, 80% in high income countries • Immunosupressant medications • Immunocompetent hosts: autoimmune disease, malignancy, immune disorder? • Higher mortality, likely due to late diagnosis CM: Presentation • • • • • Subacute headache Confusion Increased ICP-> CN palsies, seizures Meningism <20% of patients Cryptococcomas (granulomas) -> hydrocephalus, blindness • Ocular (papilledema, uveitis, chorioretinitis, optic nerve dysfunction) • Pulmonary, cutaneous, and bloodstream infections also occur CM: Diagnosis • Lumbar puncture • Elevated opening pressure • Associated with greater fungal burden and higher mortality • • • • • Lymphocytic pleocytosis Low glucose, elevated protein May be normal, especially with underlying HIV India ink staining, light microscropy: variable sensitivity Cryptococcal antigen: latex-agglutination test or lateral flow immunoassay (LFA) • LFA may be used with urine sample • Fungal culture on Sabouraud media, grows after 36 hours • Radiology: role is to detect complications • Cryptococcomas and pseudocysts in midbrain or basal ganglia • Dilated perivascular spaces • Hydrocephalus CM: Treatment IDSA and WHO Guidelines • Rate of fungal clearance from CSF in first 2 weeks (early fungicidal activity) predicts 10 week survival • CSF sterilization by 14 days predicts long term prognosis CM: Treatment • Amphotericin B • SEs: nephrotoxicity, hypokalemia, hypomagnesemia • Lipid formulations are less nephrotoxic • Greatest early fungicidal activity • Flucytosine • SEs: bone marrow suppression • Reduction of raised ICP • Serial LPs, CSF drainage catheter, VP shunt • Acetazolamide may cause harm • Management of immune reconstitution inflammatory syndrome (IRIS) • ART for HIV patients: start 4-10 weeks after initiating antifungal treatment, however need further research Cryptococcal meningitis Neuropathology Cryptococcal meningitis Neuropathology • Fungal meningitis • Crypto • • • • H&E PAS Mucicarmine GMS • Aspergillus • H&E • GMS • Tuberculosis • H&E • FITE • Streptococcal meningitis • H&E • Gram Stain • Viral meningitis • Enteroviral meningitis • H&E • CMV radiculitis • H&E Back to the case, data further on in hospital course • CT C/A/P: negative for malignancy • WNL: paraneoplastic panel, HIV • CSF: • Fungal culture: Light Cryptococcos neoformans var. grubii • Negative AFB Hospital Course • Patient had 6 more LPs…. LP OP WBC Neut Lymph Mono RBC Glucose Protein Crypt ag titer #3 (7/2) 25 9 7 63 26 5 <10 238 #4 (7/5) 26 120 2 52 25 38 <10 200 1:2048 #5 (7/9) 35 95 1 71 27 8 <10 186 1:1024 #6 (7/11) 32.8 153 1 65 26 10 10 256 1:1024 #7 (7/13) 24.2 149 2 36 46 10 <10 171 #8 (7/15) 21.8 145 2 70 28 1 11 174 • Additional CSF fungal cultures were negative Hospital Course • Improvement in personality and headache • Induction antifungal therapy extended for 1 week • Planned for Fluconazole 400mg PO daily x 8 week, followed by 200mg PO daily x 6-12 months • Discharged to home on 7/16/13 with ID follow-up in 1 week And bounce back • Patient returns on 7/27/13 with headache and dizziness, as well as difficulty with PICC. Missed several days of antifungals. LP OP #9 (7/27) 25 WBC Neut Lymph Mono RBC Glucose Protein Crypt ag titer 114 7 74 17 1 22 295 1:1024 • Discharged on 7/29/13 • Patient returns on 8/2/13 with abnormal gait and falls • Head CT obtained… Head CT 8/2/13 Brain MRI 8/2/13 MRI continued Opening pressure improving… LP OP WBC Neut Lymph Mono RBC Glucose Protein Crypt ag titer #10 (8/3) 14.5 54 4 85 8 0 19 383 1:1024 …But not MRI on 8/5/13 (3 days later) MRI Continued Patient started on Decadron per Thwaite’s protocol for TB meningitis Brain MRI 8/12/13 (1 week later) MRI Continued • Improved! Less enhancement too (not shown) • Lesions felt to be IRIS rather than cryptococcomas • Patient discharged to SNF on 8/14/13 Cryptococcomas Cryptococcomas Cryptococcomas Cryptococcomas Cryptococcomas IRIS (PML) • • • • • • H&E PAS Mucicarmine GMS CD3 IBA1 IRIS • Host immune recovery triggers inflammation in response to antigens 1. Unmasking: when cryptococcal disease occurs after starting ART in HIV patients 2. Paradoxical: initial response to antifungals, followed by deterioration after starting ART or pausing antirejection medications • May occur in immunocompetent hosts as their immune system recovers from high fungal burden • Risk factors: severe disease, slow fungal elimination • Benefit of steroids is unclear • Mortality up to 36% Back in the hospital • Returned to PUH on 9/18/13 with weakness and cough • Completed induction therapy, now on Fluconazole • Completed steroid taper (however was to continue for several more weeks) LP OP WBC Neut Lymph Mono RBC Glucose Protein Crypt ag titer #11 (9/17) 16 33 54 19 27 6 45 243 1:256 • Seen by ENT: sensorineural hearing loss. Concern for labyrinthitis ossificans 2/2 meningitis • Patient discharged home and returned on 9/25/13 with difficulty ambulating and progressive hearing loss MRI IAC 9/25/13 ID felt presentation consistent with IRIS, Decadron restarted. Patient discharged to SNF Back in the hospital • Patient returns on 12/1/13 with a headache LP OP WB C #12 (12/2) 22.5 8 prone Neut Lymph Mono RBC Glucose Protein Crypt ag titer 28 56 16 1 40 123 NEG! • Serum crypt ag remains positive (titer 1:512). Discharged from hospital. • On 8/28/14, serum titer is down to 1:16 • Per outpatient notes, discharged from ID clinic 9/2014. Doing well at home. • Patient decided not to receive cochlear implant Candida species • • • • Hyphal and yeast forms Found on skin and mucous membranes Mostly C. albicans, causing meningitis or brain abscesses Risk factors: dissemination or direct inoculation into CNS • Ex. Premature infant with neural tube defect or neurosurgical intervention • Check for 1,3-beta-D glucan in CSF (cell wall component of some fungi) • Treatment: amphotericin B + fluctytosine Aspergillus species • Septated hyphae with acute angle branching • Found in soil and decaying vegetation • Transmission via respiratory tract, CNS spread by direct route or hematogenous • Most commonly results in brain abscesses or granulomas • May also lead to vascular invasion causing infarcts, hemorrhage, mycotic aneurysms • Isolated meningitis is rare • Risk factors: immunosupression. Can occur in immunocompetent hosts • Galactomannan antigen and 1,3-beta-D glucan in CSF (not specific to aspergillosis) • Treatment: Voriconazole + Amphotericin B Zygomycetes • Ex. Mucor and Rhizopus species (broad, irregularly branched, rare septate hyphae) • Found in soil and decaying vegetation • Transmission via respiratory tract • Risk factors: • Environment rich in acid and carbohydrates (ex. Diabetic ketoacidosis) • Neutropenia • Excess iron and chelating agent deferoxamine • IVDU • Causes brain abscess and vascular invasion (infarcts, hemorrhage, mycotic aneurysms, cavernous sinus thrombosis) • Treatment: Amphotericin B Coccidioides immitis • • • • Found in Southwest US Transmitted by inhaling spores Spherules -> Endospores Causes meningitis, usually within a few months of pulmonary infection • Rarely causes brain abscesses • May affect immunocompetent hosts • Treatment: Fluconazole or Itraconazole and/or intrathecal Amphotericin B Histoplasma capsulatum • Found in Ohio and Mississippi River valleys • Yeast form, less likely hyphae • Found in soil mixed with bird or bat droppings, especially in caves • Causes meningitis, infrequently brain abscesses (miliary non-caseating granuloma) • May affect immunocompetent hosts • Treatment: Amphotericin B followed by Itraconazole References • Chakrabarti, Arunaloke. “Epidemiology of central nervous system mycoses.” Neurology India. 55;3:191-197. 2007. • McCarthy M et al. “Mold Infections of the Central Nervous System.” The New England Journal of Medicine. 371;2:150160. July 2014. • Sloan DJ and Parris V. “Cryptococcal meningitis: epidemiology and therapeutic options.” Clinical Epidemiology. 13;6:169-182. May 2014.